All posts by Scott Power
Senior Analyst
Sectors Covered: Healthcare, Life Sciences
By Scott Power
24 August 2023, 8:00 AM
Ebos Group (ASX:EBO) reported another year of consistent earnings growth (up 14.1%) which benefitted from acquisitions in the medical technology and consumables category.
Read more...
By Scott Power
23 August 2023, 8:00 AM
Nanosonics' (ASX:NAN) FY23 results came in at the top end of guidance however focus centred around timing of CORIS®, which has been delayed by at least six months. Disappointing, but not unsurprising.
Read more...
By Scott Power
08 June 2023, 8:00 AM
Ebos Group (ASX:EBO) has announced it has lost the contract to supply wholesale PBS medicines to Chemist Warehouse (CW) from July 2024.
Read more...
By Scott Power
01 June 2023, 8:00 AM
We have been looking for an opportunity to upgrade Nanosonics (ASX:NAN) back to Add (from Hold) and given the recent share price weakness, we now have ~10% upside to our increased target price.
Read more...
By Scott Power
05 May 2023, 8:00 AM
Nanosonics' (ASX:NAN) share price has gone through our target price and as a result we have moved our recommendation back to Hold (from Add).
Read more...
By Scott Power
24 February 2023, 8:00 AM
Nanosonics (ASX:NAN) posted a solid 1H23 result which was in line with forecasts and FY23 guidance was reconfirmed.
Read more...
By Scott Power
22 November 2022, 7:00 AM
At its AGM Nanosonics (ASX:NAN) provided a four-month trading update which showed a solid start to the year, with revenue up 42% and an increase in the installed base of 814 units.
Read more...
By Scott Power
24 August 2022, 7:00 AM
Nanosonics (ASX:NAN) posted an in-line FY22 result, assisted by lower operating costs and a tax benefit.
Read more...
By Scott Power
26 May 2022, 9:30 AM
Nanosonics (ASX:NAN) provided a solid trading update with 3Q sales and installed base growing in line with 2Q, the company noted it anticipates FY22 revenue will be in line with consensus.
Read more...
By Scott Power
21 October 2021, 8:00 AM
We have realigned our cost base in line with management guidance. This has resulted in a downgraded to our short-term forecasts.
Read more...